MetaCap

Purple Biotech (PPBT) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Purple Biotech is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PPBT+4.45%PRFX-45.79%
+20%-14%-49%
Oct 7, 20261 yearNov 20, 2026
PPBT+14.66%PRFX-45.86%
+26%-12%-49%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PPBT versus PRFX key metrics
MetricPPBTPRFX
Share price$1.53$0.4758
Market cap$1.86M$1.66M
1-day change-4.09%-23.68%
EPS (TTM)$-47.64$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$17.00K
Net income (latest FY)$-26.39M$-5.02M
Gross margin—-311.76%
Operating margin—-30129.41%
Net margin—-29541.18%
52-week high$8.90$7.95
52-week low$0.91$0.46
Distance from 52-week high-82.87%-94.02%
Analyst consensusnone—
Avg. price target upside+1014.75%—
Average volume1.26M228.55K
Shares outstanding1.22M3.50M
Employees106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

PPBT vs PRFX FAQ

Which is bigger, Purple Biotech or PRF Technologies?

Purple Biotech (PPBT) is larger, with a market capitalization of $1.86M compared with $1.66M for PRF Technologies (PRFX).

Are Purple Biotech and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons